메뉴 건너뛰기




Volumn 370, Issue 22, 2014, Pages 2083-2092

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

(17)  King Jr , Talmadge E a   Bradford, Williamson Z b   Castro Bernardini, Socorro d   Fagan, Elizabeth A b   Glaspole, Ian e   Glassberg, Marilyn K g   Gorina, Eduard b   Hopkins, Peter M f   Kardatzke, David b   Lancaster, Lisa h   Lederer, David J i   Nathan, Steven D j   Pereira, Carlos A k   Sahn, Steven A l   Sussman, Robert m   Swigris, Jeffrey J n   Noble, Paul W c  


Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PIRFENIDONE; PLACEBO;

EID: 84901759236     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1402582     Document Type: Article
Times cited : (2935)

References (27)
  • 1
    • 79952717349 scopus 로고    scopus 로고
    • An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management
    • Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
    • (2011) Am J Respir Crit Care Med , vol.183 , pp. 788-824
    • Raghu, G.1    Collard, H.R.2    Egan, J.J.3
  • 2
    • 20544443765 scopus 로고    scopus 로고
    • The clinical course of patients with idiopathic pulmonary fibrosis
    • Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963-7.
    • (2005) Ann Intern Med , vol.142 , pp. 963-967
    • Martinez, F.J.1    Safrin, S.2    Weycker, D.3
  • 3
    • 0034520079 scopus 로고    scopus 로고
    • The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis
    • Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000;162:2213-7. (Pubitemid 32051689)
    • (2000) American Journal of Respiratory and Critical Care Medicine , vol.162 , Issue.6 , pp. 2213-2217
    • Nicholson, A.G.1    Colby, T.V.2    Dubois, R.M.3    Hansell, D.M.4    Wells, A.U.5
  • 6
    • 17644421000 scopus 로고    scopus 로고
    • Surveillance, Epidemiology, and End Results Program (SEER)
    • Surveillance, Epidemiology, and End Results Program (SEER). SEER cancer statistics review, 2003-2009 (http://seer.cancer.gov).
    • (2003) SEER Cancer Statistics Review
  • 7
    • 77951160564 scopus 로고    scopus 로고
    • Pirfenidone in idiopathic pulmonary fibrosis
    • Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9.
    • (2010) Eur Respir J , vol.35 , pp. 821-829
    • Taniguchi, H.1    Ebina, M.2    Kondoh, Y.3
  • 8
    • 79956341531 scopus 로고    scopus 로고
    • Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials
    • Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
    • (2011) Lancet , vol.377 , pp. 1760-1769
    • Noble, P.W.1    Albera, C.2    Bradford, W.Z.3
  • 10
    • 33645762226 scopus 로고
    • A sharper Bonferroni procedure for multiple tests of significance
    • Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
    • (1988) Biometrika , vol.75 , pp. 800-802
    • Hochberg, Y.1
  • 12
    • 84901793089 scopus 로고    scopus 로고
    • Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
    • in press
    • Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology (in press).
    • Respirology
    • Valeyre, D.1    Albera, C.2    Bradford, W.Z.3
  • 13
    • 67650349068 scopus 로고    scopus 로고
    • Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicentre, randomised, placebo-controlled trial
    • King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374:222-8.
    • (2009) Lancet , vol.374 , pp. 222-228
    • King Jr., T.E.1    Albera, C.2    Bradford, W.Z.3
  • 14
    • 84455168726 scopus 로고    scopus 로고
    • Forced vital capacity in patients with idiopathic pulmonary fibrosis: Test properties and minimal clinically important difference
    • du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382-9.
    • (2011) Am J Respir Crit Care Med , vol.184 , pp. 1382-1389
    • Du Bois, R.M.1    Weycker, D.2    Albera, C.3
  • 15
    • 79955520497 scopus 로고    scopus 로고
    • Six-minute-walk test in idiopathic pulmonary fibrosis: Test validation and minimal clinically important difference
    • du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011;183:1231-7.
    • (2011) Am J Respir Crit Care Med , vol.183 , pp. 1231-1237
    • Du Bois, R.M.1    Weycker, D.2    Albera, C.3
  • 19
    • 13844316832 scopus 로고    scopus 로고
    • Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis
    • DOI 10.1378/chest.127.1.171
    • King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-7. (Pubitemid 41724573)
    • (2005) Chest , vol.127 , Issue.1 , pp. 171-177
    • King Jr., T.E.1    Safrin, S.2    Starko, K.M.3    Brown, K.K.4    Noble, P.W.5    Raghu, G.6    Schwartz, D.A.7
  • 20
    • 77951170794 scopus 로고    scopus 로고
    • Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
    • Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2009;35:830-6.
    • (2009) Eur Respir J , vol.35 , pp. 830-836
    • Zappala, C.J.1    Latsi, P.I.2    Nicholson, A.G.3
  • 21
    • 84862826491 scopus 로고    scopus 로고
    • Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
    • Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012;67:407-11.
    • (2012) Thorax , vol.67 , pp. 407-411
    • Richeldi, L.1    Ryerson, C.J.2    Lee, J.S.3
  • 22
    • 80051819865 scopus 로고    scopus 로고
    • Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis
    • du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:459-66.
    • (2011) Am J Respir Crit Care Med , vol.184 , pp. 459-466
    • Du Bois, R.M.1    Weycker, D.2    Albera, C.3
  • 23
    • 84899830690 scopus 로고    scopus 로고
    • 6-Minute walk test distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis
    • du Bois RM, Albera C, Bradford WZ, et al. 6-Minute walk test distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014;43:1421-9.
    • (2014) Eur Respir J , vol.43 , pp. 1421-1429
    • Du Bois, R.M.1    Albera, C.2    Bradford, W.Z.3
  • 24
    • 57949084974 scopus 로고    scopus 로고
    • Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis
    • Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009;103:117-23.
    • (2009) Respir Med , vol.103 , pp. 117-123
    • Caminati, A.1    Bianchi, A.2    Cassandro, R.3    Mirenda, M.R.4    Harari, S.5
  • 25
    • 69249235753 scopus 로고    scopus 로고
    • Small changes in six-minute walk distance are important in diffuse parenchymal lung disease
    • Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med 2009;103:1430-5.
    • (2009) Respir Med , vol.103 , pp. 1430-1435
    • Holland, A.E.1    Hill, C.J.2    Conron, M.3    Munro, P.4    McDonald, C.F.5
  • 26
    • 76549135612 scopus 로고    scopus 로고
    • The 6 minute walk in idiopathic pulmonary fibrosis: Longitudinal changes and minimum important difference
    • Swigris JJ, Wamboldt FS, Behr J, et al. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010;65:173-7.
    • (2010) Thorax , vol.65 , pp. 173-177
    • Swigris, J.J.1    Wamboldt, F.S.2    Behr, J.3
  • 27
    • 84897459884 scopus 로고    scopus 로고
    • All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials
    • King TE Jr, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014;189:825-31.
    • (2014) Am J Respir Crit Care Med , vol.189 , pp. 825-831
    • King Jr., T.E.1    Albera, C.2    Bradford, W.Z.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.